L’utilisation des anticorps monoclonaux dans le cancer de l’ovaire

  • È.-M. Neidhardt
Part of the Abord clinique book series (ONCOLPRAT)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Berk JS (2000) Epithelial ovarian cancer, in Berek JS, Jacker NF (eds). Practical Gynecologic Oncology, 3rd ed. Philadelphia, PA, lippincott Williams & Wilkins 457–522Google Scholar
  2. 2.
    Bast RC Jr, Klug TL, St John E et al. (1983) A radio-immunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Cancer 309: 883–7Google Scholar
  3. 3.
    Yin BWT, Dnistrian A, Llyod KO (2002) Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 98: 737–40CrossRefPubMedGoogle Scholar
  4. 4.
    O’Brien TJ, Beard JB, Undewood LJ et al. (2002) The CA125 gene: A newly discoveredextension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. Tumour Biol 23: 154–69PubMedGoogle Scholar
  5. 5.
    Noujaim AA, Schultes BC, Baum RP et al. (2001) Induction of CA125-specific B and T cell responses in patients injected withe Mab-B43.13: Evidence for antibody-mediated antigenprocessing and presentation of CA125 in vivo. Cancer Biother Radio-pharm 16: 187–203Google Scholar
  6. 6.
    Schultes BC, Baum RP, Niesen A et al. (1998) Anti-idiotype induction therapy: Anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with OvaRex Mab B43.13 (Ab1). Cancer Immunol Immunother 46: 201–12CrossRefPubMedGoogle Scholar
  7. 7.
    Schultes BC, Kuzma ML, Agoposowicz K et al. (2003) Antibodies as vaccine: Immune complexes allow for efficient uptake and processing of antigens on MHC class I and II and induce maturation of dendritic cells. FASEB J 16: A334 (abst 246.12)Google Scholar
  8. 8.
    Gordon AN, Schultes C, Gallion H et al. (2004) CA125-and tumor-specific-T-cell responses correlate with survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 94: 340–51PubMedGoogle Scholar
  9. 9.
    Schultes BC, Zhang C, Xue LY et al. (1999) Immunotherapy of human ovarian carcinoma with OvaRex Mab B43.13 in a human-PBL-SCID/BG mouse model. Hybridoma 18: 47–55PubMedGoogle Scholar
  10. 10.
    Noujaim AA, Baum RP, Sykes TR et al. (1994) Monoclonal antibody B43.13 for immunoscintigraphy and immunotherapy of ovarian cancer, in Klapdor R (ed): Current Tumor diagnosis: Application, Clinical Relevance, Trends. Munchen, Germany, W Zuckschwerdt Verlag, 823–9Google Scholar
  11. 11.
    Elhen TG, Gordon AN, Fingert HJ et al. (2002) Adjuvant treatment with monoclonal antibody, OvaRex Mab B43.13 (OV) targeting CA125, induces robust immune responses associated with prolonged time to relapse (TTR) in a randomized, placebo-controlled study in patients with advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 21: 9a (abstr 31)Google Scholar
  12. 12.
    Berek JS, Peyton TT, Gordon A et al. (2004) Randomized, Placebo-Controlled study of Oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 22: 3507–16CrossRefPubMedGoogle Scholar
  13. 13.
    Gordon A, Whiteside T, Nicodemus C et al. (2001) An interim assessment of OvaRex Mab B43.13. Proc Am Soc Clin Oncol 20: 187b (abstr 2499)Google Scholar
  14. 14.
    Mobüs VJ, Baum RP, Bolle M et al. (2003) Immune Responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. Am J Obstet Gynecol 189: 28–36PubMedGoogle Scholar
  15. 15.
    Taylor-Papadimitriou J, Burchell J, Miles D et al. (1999) MUC1 and Cancer. Biochim Biophys Acta 1455: 301PubMedGoogle Scholar
  16. 16.
    Hird V, Maraveyas A, Snook D et al. (1993) Adjuvant therapy of ovarian cancer with radioactive monoclonal antibodies. Brit J of Cancer 68: 403–6Google Scholar
  17. 17.
    Nicholson S, Bomphray CC, Thomas H et al. (2004) A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancerGoogle Scholar
  18. 18.
    Bookman MA, Darcy KM, Clarke-Pearson D et al. (2003) Evaluation of monoclonal humanized anti-HER2 anti-body, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21(2): 283–90CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • È.-M. Neidhardt

There are no affiliations available

Personalised recommendations